{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:40:19Z","timestamp":1792611619697,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern. There were only a few studies on CAR-T cardiotoxicity published to date with limited sample sizes, and their findings were heterogeneous. It was difficult to reach generalizable conclusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>CAR-T therapy was associated with significant risks for acute and subacute cardiotoxicity, as measured by echocardiograms, EKG, and blood biomarkers. Patients with cytokine release syndrome (CRS) grade 2 or higher were more likely to exhibit cardiotoxicity. The most prevalent cardiac events included hypotension-requiring inotropic or vasopressor support, tachycardia, heart failure\/decompensation, atrial fibrillation, new or worsening cardiomyopathy, arrhythmia, myocarditis, cardiac arrest, and cardiovascular death. The most prevalent echocardiographic changes were systolic dysfunction and diastolic dysfunction, and abnormal echocardiogram findings. There were differences in findings between adult and pediatric patients. The long-term effects beyond a year post treatment remain largely unknown and long-term follow-up studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-024-01634-2","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T06:49:25Z","timestamp":1737442165000},"page":"135-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review"],"prefix":"10.1007","volume":"27","author":[{"given":"Tony","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Alejandro","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim Q.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"1634_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22. https:\/\/doi.org\/10.1186\/s40364-017-0102-y.","journal-title":"Biomark Res"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049.","journal-title":"Front Immunol"},{"key":"1634_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","volume":"2","author":"AK Ghosh","year":"2020","unstructured":"Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncol. 2020;2:97\u2013109. https:\/\/doi.org\/10.1016\/j.jaccao.2020.02.011.","journal-title":"JACC CardioOncol"},{"key":"1634_CR5","doi-asserted-by":"publisher","unstructured":"Chacko S, Haseeb S, Glover BM, Wallbridge D, Harper A (2018)The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome. Future science OA. 4(1):FSO251.https:\/\/doi.org\/10.4155\/fsoa-2017-0036.","DOI":"10.4155\/fsoa-2017-0036"},{"key":"1634_CR6","doi-asserted-by":"publisher","first-page":"1090103","DOI":"10.3389\/fcvm.2023.1090103","volume":"10","author":"M Camilli","year":"2023","unstructured":"Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, Lombardo A. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Front Cardiovasc Med. 2023;10:1090103. https:\/\/doi.org\/10.3389\/fcvm.2023.1090103.","journal-title":"Front Cardiovasc Med"},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40:367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"1634_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1634_CR9","doi-asserted-by":"publisher","first-page":"932347","DOI":"10.3389\/fcvm.2022.932347","volume":"9","author":"A Rao","year":"2022","unstructured":"Rao A, Stewart A, Eljalby M, Ramakrishnan P, Anderson LD Jr, Awan FT, Chandra A, Vallabhaneni S, Zhang K, Zaha VG. Cardiovascular disease and chimeric antigen receptor cellular therapy. Front Cardiovasc Med. 2022;9:932347. https:\/\/doi.org\/10.3389\/fcvm.2022.932347.","journal-title":"Front Cardiovasc Med"},{"key":"1634_CR10","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. J Immunol Res. 2018;2018:2386187. https:\/\/doi.org\/10.1155\/2018\/2386187.","journal-title":"J Immunol Res"},{"key":"1634_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11912-019-0753-y","volume":"21","author":"I Aldoss","year":"2019","unstructured":"Aldoss I, Khaled SK, Budde E, Stein AS. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment. Curr Oncol Rep. 2019;21:4. https:\/\/doi.org\/10.1007\/s11912-019-0753-y.","journal-title":"Curr Oncol Rep"},{"key":"1634_CR12","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, et al. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019;74:3099\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.038.","journal-title":"J Am Coll Cardiol"},{"key":"1634_CR13","doi-asserted-by":"publisher","unstructured":"Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J ImmunoTher Cancer. 2021;9(8).https:\/\/doi.org\/10.1136\/jitc-2020-002303.","DOI":"10.1136\/jitc-2020-002303"},{"key":"1634_CR14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","volume":"24","author":"DS Burstein","year":"2018","unstructured":"Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. Biol Blood Marrow Transplant. 2018;24:1590\u20135. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.014.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1634_CR15","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017;45:e124\u201331. https:\/\/doi.org\/10.1097\/CCM.0000000000002053.","journal-title":"Crit Care Med"},{"key":"1634_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, Spendley L, Nikiforow S, Jacobson C, Nohria A. Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. Circulation. 2020;142:1687\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048100.","journal-title":"Circulation"},{"key":"1634_CR17","doi-asserted-by":"publisher","first-page":"102504","DOI":"10.1016\/j.eclinm.2024.102504","volume":"69","author":"F Korell","year":"2024","unstructured":"Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, Muller-Tidow C, Frey N, Dreger P, Schmitt M, Lehmann LH. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine. 2024;69:102504. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102504.","journal-title":"EClinicalMedicine"},{"key":"1634_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-023-00170-5","volume":"9","author":"DH Lee","year":"2023","unstructured":"Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, et al. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023;9:18. https:\/\/doi.org\/10.1186\/s40959-023-00170-5.","journal-title":"Cardiooncology"},{"key":"1634_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study. JACC CardioOncol. 2020;2:193\u2013203. https:\/\/doi.org\/10.1016\/j.jaccao.2020.04.012.","journal-title":"JACC CardioOncol"},{"key":"1634_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","volume":"5","author":"B Lefebvre","year":"2023","unstructured":"Lefebvre B, Kang Y, Vakilpour A, Onoue T, Frey NV, Brahmbhatt P, Huang B, Oladuja K, Koropeckyj-Cox D, Wiredu C, et al. Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study. JACC CardioOncol. 2023;5:747\u201354. https:\/\/doi.org\/10.1016\/j.jaccao.2023.07.009.","journal-title":"JACC CardioOncol"},{"key":"1634_CR21","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"1634_CR22","doi-asserted-by":"publisher","unstructured":"Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, Sidenko S, Delbrook C, Mackall C, Wiley B, et al. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer 2020, 8, https:\/\/doi.org\/10.1136\/jitc-2020-001159","DOI":"10.1136\/jitc-2020-001159"},{"key":"1634_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19497","author":"R Shouval","year":"2024","unstructured":"Shouval R, Goldman A, Flynn JR, El-Moghraby A, Rehman M, Devlin SM, Corona M, Landego I, Lin RJ, Scordo M, et al. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile. Br J Haematol. 2024. https:\/\/doi.org\/10.1111\/bjh.19497.","journal-title":"Br J Haematol"},{"issue":"3","key":"1634_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","volume":"15","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y. (2023) CAR-T: What Is Next? Cancers (Basel). 2023;15(3):663. https:\/\/doi.org\/10.3390\/cancers15030663.","journal-title":"Cancers (Basel)"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01634-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:55:05Z","timestamp":1740462905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01634-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01634-2","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"30 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}